Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy Elaine M. WalshAliaa ShalabyGrace M. Callagy Editorial Open access 28 November 2018 Pages: 1 - 13
Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies Raquel N. RoznerAzael Freites-MartinezMario E. Lacouture Review 22 November 2018 Pages: 15 - 26
Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials Rafael CaparicaMarco BruzzoneMatteo Lambertini Review 21 November 2018 Pages: 27 - 37
Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE) Danielle A. HenryMarie C. LeeChristine Laronga Review 24 November 2018 Pages: 39 - 45
Survivorship issues in older breast cancer survivors Steven S. CoughlinRaheem J. PaxtonJudith Anglin Review 01 December 2018 Pages: 47 - 53
Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations Lynn JongenGiuseppe FlorisHans Wildiers Preclinical study 19 November 2018 Pages: 55 - 63
GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation Jingjing LiuLei LiuJin Zhang Preclinical study 19 November 2018 Pages: 65 - 78
Glutamate dehydrogenase (GLUD1) expression in breast cancer Madeleine L. CrazeRokaya El-AnsariAndrew R. Green Preclinical study 23 November 2018 Pages: 79 - 91
Connexin 43 is an independent predictor of patient outcome in breast cancer patients Maria ChasampaliotiAndrew R. GreenJudith M. Ramage Preclinical study Open access 24 November 2018 Pages: 93 - 102
Prognostic impact and possible pathogenesis of lymph node metastasis in ductal carcinoma in situ of the breast Rika YonekuraTomo OsakoFutoshi Akiyama Preclinical study 24 November 2018 Pages: 103 - 111
ANXA2 expression in African American triple-negative breast cancer patients Lee D. GibbsPankaj ChaudharyJamboor K. Vishwanatha Preclinical study 26 November 2018 Pages: 113 - 120
G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen Tanja IgnatovMaria ClausAtanas Ignatov Preclinical study 26 November 2018 Pages: 121 - 127
Plasma exosomes stimulate breast cancer metastasis through surface interactions and activation of FAK signaling Tatiana ShtamStanislav NaryzhnyAnastasia Malek Preclinical study 27 November 2018 Pages: 129 - 141
A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer Daniel P. HollernCristina M. ContrerasCharles M. Perou Preclinical study Open access 27 November 2018 Pages: 143 - 155
A phase II study investigating the acute toxicity of targeted intraoperative radiotherapy as tumor-bed boost plus whole breast irradiation after breast-conserving surgery in Korean patients Sung Gwe AhnSoong June BaeJoon Jeong Clinical trial 22 November 2018 Pages: 157 - 163
Meta-analysis of upgrade rates in 3163 radial scars excised after needle core biopsy diagnosis Gelareh FarshidElizabeth Buckley Clinical trial 20 November 2018 Pages: 165 - 177
Evaluation of radiation-induced cardiac toxicity in breast cancer patients treated with Trastuzumab-based chemotherapy Mohamed AbouegylahLior Z. BraunsteinAlphonse G. Taghian Clinical trial 26 November 2018 Pages: 179 - 185
A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study Elisabet LidbrinkE. ChmielowskaV. Misra Clinical Trial Open access 30 November 2018 Pages: 187 - 196
Impact of preexisting mental illness on breast cancer endocrine therapy adherence Cole B. HaskinsBradley D. McDowellElizabeth A. Chrischilles Epidemiology 21 November 2018 Pages: 197 - 208
Metabolic syndrome and risk of breast cancer mortality by menopause, obesity, and subtype Daniel T. DibabaKemi OgunsinaTomi Akinyemiju Epidemiology 21 November 2018 Pages: 209 - 218
Sleep duration and risk of breast cancer: The JACC Study Jinhong CaoEhab S. EshakJACC Study Group Epidemiology 20 November 2018 Pages: 219 - 225
Time-varying risks of second events following a DCIS diagnosis in the population-based Vermont DCIS cohort Brian L. SpraguePamela M. VacekDonald L. Weaver Epidemiology 17 November 2018 Pages: 227 - 235
A nationwide study of breast cancer, depression, and multimorbidity among hospitalized women and men in the United States Roger J. ZoorobJason L. SalemiRobert S. Levine Epidemiology 21 November 2018 Pages: 237 - 248
Milk intake and mammographic density in premenopausal women Yunan HanXiaoyu ZongAdetunji T. Toriola Epidemiology 20 November 2018 Pages: 249 - 255
MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population Lenora W. M. LooChong GaoJill Bargonetti Epidemiology 23 November 2018 Pages: 257 - 269
The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis Kirsty Wai Chung LeeSally LordChee Khoon Lee Brief Report 21 November 2018 Pages: 271 - 278
